Top Markets
Coin of the day
Relmada Therapeutics, Inc. Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

RLMD
Clasificación en acciones #13828
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company... Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Precio por acción
$4.36
Capitalización bursátil
$457.32M
Cambio (1 día)
0.69%
Cambio (1 año)
289.29%
País
US
Comercio Relmada Therapeutics, Inc. (RLMD)

Categoría

Historial de rendimiento por dividendo de Relmada Therapeutics, Inc. (RLMD)
Rendimiento por dividendo (TTM) de Relmada Therapeutics, Inc. (símbolo bursátil: RLMD) al 2026: 0
Rendimiento promedio por dividendo de los últimos 5 años: 0.00%
Historial de rendimiento por dividendo de Relmada Therapeutics, Inc. (RLMD) desde 2026 hasta 2026
Rendimiento por dividendo al final de cada año (TTM)
Año Rendimiento por dividendo Cambiar
Not enough data for the provided dates.
Rendimientos por dividendo (TTM) de empresas similares o competidoras
Empresa Rendimiento por dividendo País
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH